Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. on October 20, 2017, covering events that occurred on October 16 and October 18, 2017. The filing addresses corporate governance changes regarding the Board of Directors. Note: The request metadata references "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting personnel changes.
Material Changes
- Resignations: Thomas H. Aasen and Eugene A. Bauer resigned from the Board of Directors effective immediately on October 16 and October 18, 2017, respectively.
- Committee Roles: Mr. Aasen was a member of the audit committee; Dr. Bauer was a member of the nominating and corporate governance committee.
- Reason for Departure: The resignations were not the result of any disagreement with the Company.
- Appointment: Peter Greenleaf was appointed to the audit committee to replace Mr. Aasen.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the board changes.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and committee memberships following the appointment of Peter Greenleaf.
- Confirm that the resignations of Mr. Aasen and Dr. Bauer were indeed amicable and unrelated to any undisclosed disagreements.
- Review subsequent filings to determine if additional board vacancies were filled or if further governance changes occurred.